Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2653-2664

  Pelletier, Elise M ^a   Ogale, Sarika ^b   Yu, Elaine ^b   Brunetta, Paul ^b   Garg, Jay ^b  

^a IQVIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

administrative claims; lupus; managed care; medical costs; nephritis; resource utilization; SLE

Indexed keywords

ADALIMUMAB; ANTICOAGULANT AGENT; AZATHIOPRINE; BETAMETHASONE; CELECOXIB; CHLORAMBUCIL; CHLOROQUINE; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DICLOFENAC; ETANERCEPT; ETODOLAC; FENOPROFEN; FLURBIPROFEN; HYDROCORTISONE; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; INFLIXIMAB; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALICYLIC ACID; UNINDEXED DRUG;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEMODIALYSIS; HOSPITAL CARE; HOSPITALIZATION; HUMAN; KIDNEY TRANSPLANTATION; LABORATORY TEST; LENGTH OF STAY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PERITONEAL DIALYSIS; PHARMACEUTICAL CARE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADULT; AGED; AMBULATORY CARE; COMMUNITY PHARMACY SERVICES; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEPHRITIS; TREATMENT OUTCOME; UNITED STATES;

EID: 74549156551     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.032     Document Type: Article

References (21)

1. Chakravarty E.F., Bush T.M., Manzi S., et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis Rheum. 56 (2007) 2092-2094
2. Balluz L., Philen R., Ortega L., et al. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am J Epidemiol. 154 (2001) 1029-1036
3. Gladman D.D., Urowitz M.B., Rahman P., et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 30 (2003) 1955-1959
4. Cameron J.S. Lupus nephritis. J Am Soc Nephrol. 10 (1999) 413-424
5. Clarke A.E., Panopalis P., Petri M., et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford). 47 (2008) 329-333
6. Stoll T., Seifert B., and Isenberg D.A. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcomes in patients with systemic lupus erythematosus. Br J Rheumatol. 35 (1996) 248-254
7. Panopalis P., and Clarke A.E. Quality of life in systemic lupus erythematosus. Clin Dev Immunol. 13 (2006) 321-324
8. Thumboo J., and Strand V. Health-related quality of life in patients with systemic lupus erythematosus: An update. Ann Acad Med Singapore. 36 (2007) 115-122
9. Clarke A. Economic impact of lupus. Am J Manag Care. 7 Suppl 16 (2001) S496-S501
10. Clarke A.E., Petri M., Manzi S., et al., Tri-Nation Study Group. The systemic lupus erythematosus Tri-Nation Study: Absence of a link between health resource use and health outcome. Rheumatology (Oxford). 43 (2004) 1016-1024
11. Panopalis P., Petri M., Manzi S., et al., Tri-Nation Study Group. The systemic lupus erythematosus Tri-Nation Study: Cumulative indirect costs. Arthritis Rheum. 57 (2007) 64-70
12. Wilson E.C., Jayne D.R., Dellow E., and Fordham R.J. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology (Oxford). 46 (2007) 1096-1101
13. World Health Organization. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (2003), WHO, Geneva, Switzerland
14. American Medical Association (AMA). Current Procedural Terminology: 2001 (2000), AMA, Chicago, Ill
15. Health Insurance Portability and Accountability Act (HIPAA), Pub. L. No. 104-191,110 Stat. 1936 (2006) (1996)
16. Romano P.S., Roos L.L., and Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 46 (1993) 1075-1079 discussion
17. Romano P.S., Roos L.L., and Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 46 (1993) 1081-1090
18. US Dept of Labor, Bureau of Labor Statistics. Consumer Price Index for the Healthcare Sector, 2006 (2006), Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes, Washington, DC
19. Carls G., Li T., Panopalis P., et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 51 (2009) 66-79
20. Altman D., Cutler D., and Zeckhauser R. Enrollee mix, treatment intensity, and cost in competing indemnity and HMO plans. J Health Econ. 22 (2003) 23-45
21. Huscher D., Merkesdal S., Thiele K., et al., German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 65 (2006) 1175-1183